The following patients may be selected to participate in the survey:
- Those undergoing treatment with eplerenone in accordance with the MA or not, with a
known start date.
- Those likely to be followed by the same physician for a minimal period of twelve
- Severe Kidney Disease
- Hyperkamiemia more than 5.5